Selvita Overview

  • Founded
  • 2007
  • Status
  • Public
  • Employees
  • 158
  • Stock Symbol
  • RVU
Stock Symbol
  • Investments
  • 4
  • Share Price
  • $13.98
  • (As of Friday Closing)

Selvita General Information


Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
Primary Office
  • Park Life Science
  • Ul. Bobrzyńskiego 14
  • Krakow, 30-348
  • Poland
+48 12 000 00 00

Selvita Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Selvita Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.98 $14.13 $7.21 - $20.38 $257M 18.4M 14.4K

Selvita Financials Summary

In Thousands,
TTM 30-Sep-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017 FY 2016 31-Dec-2016
EV 222,419 179,924 219,637 85,436
Revenue 18,975 21,365 23,245 13,723
EBITDA (7,023) 4,464 3,972 536
Net Income (9,993) (29) 1,696 689
Total Assets 67,520 67,947 29,750 21,282
Total Debt 3,599 3,580 2,296 2,298
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Selvita Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Selvita‘s full profile, request access.

Request a free trial

Selvita Executive Team (6)

Name Title Board Seat Contact Info
Bogusław Sieczkowski Co-Founder & Chief Executive Officer
Krzysztof Brzozka Ph.D Executive Vice President and Chief Scientific Officer
Magdalena Marciniak Business Alliance Manager
Pawel Przewiezlikowski Co-Founder & Chief Executive Officer
Setareh Shamsili Ph.D Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Selvita Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Selvita Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Selvita‘s full profile, request access.

Request a free trial

Selvita Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 23-Nov-2020 000000000000000000 000.00 Drug Discovery
00000000 01-Aug-2016 0000 00000 00.000 Biotechnology
0000000000 21-Oct-2010 000000000 00000000 Biotechnology 00000ł00 00000000000
BioCentrum 31-Mar-2008 Merger/Acquisition Biotechnology 00000 0000000000000000
To view Selvita’s complete investments and acquisitions history, request access »

Selvita Subsidiaries (1)

Company Name Industry Location Founded
0000000000 Biotechnology Krakow, Poland 0000
To view Selvita’s complete subsidiaries history, request access »